Plain-English translation of NCT07040813 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Migraine research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether combining two different migraine prevention medications—a CGRP monoclonal antibody and onabotulinumtoxin A (Botox)—works better than using just the CGRP medication alone. Right now, many people with chronic migraine don't get enough relief from either treatment by itself, so researchers want to see if using both together might help more.
Even with today's best migraine treatments, many patients still suffer from frequent migraines and poor quality of life. This study exists to find out if combining two different medications that work in different ways might reduce migraine days more effectively than using either one alone.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic 3 times and have 3 phone calls over 20 weeks total. Half the participants will receive both the CGRP medication and Botox injections, while the other half will receive the CGRP medication plus a placebo injection (a harmless salt solution). You'll keep a daily headache diary using a smartphone app to track your migraine days, and researchers will measure how many migraine days you have during the 12-week treatment period.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Norway